<code id='E3BAABD88C'></code><style id='E3BAABD88C'></style>
    • <acronym id='E3BAABD88C'></acronym>
      <center id='E3BAABD88C'><center id='E3BAABD88C'><tfoot id='E3BAABD88C'></tfoot></center><abbr id='E3BAABD88C'><dir id='E3BAABD88C'><tfoot id='E3BAABD88C'></tfoot><noframes id='E3BAABD88C'>

    • <optgroup id='E3BAABD88C'><strike id='E3BAABD88C'><sup id='E3BAABD88C'></sup></strike><code id='E3BAABD88C'></code></optgroup>
        1. <b id='E3BAABD88C'><label id='E3BAABD88C'><select id='E3BAABD88C'><dt id='E3BAABD88C'><span id='E3BAABD88C'></span></dt></select></label></b><u id='E3BAABD88C'></u>
          <i id='E3BAABD88C'><strike id='E3BAABD88C'><tt id='E3BAABD88C'><pre id='E3BAABD88C'></pre></tt></strike></i>

          knowledge

          knowledge

          author:leisure time    Page View:695
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal
          Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

          CarstenSnejbjerg/BloombergLONDON—TheinvestmentarmofNovoNordisk’sparentfoundationisbuyingdrugmanufact

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Decaf coffee targeted by food safety group under obscure FDA rule

          ApichartWeerawong/APWASHINGTON—There’safightbrewingoverthefutureofdecafcoffee.Consumerhealthadvocate